protease produced in the kidney that converts plasminogen to plasmin and so initiates fibrinolysis

objective to explore the relationship between plasminogen activator inhibitor type-1 (pai-1)and its biological behaviour of hepatocellular carcinoma (hcc).

目的研究纤溶酶原激活物抑制剂（pai-1）与肝癌临床生物学特性的关系。

objective to investigate the relationship between the plasminogen activator inhibitor 1(pai 1) promotor region gene polymorphism and cerebral stroke.

目的探讨纤溶酶原激活物抑制物- 1（pai-1）启动子区基因多态性与脑卒中的关系。

aim: to observe the effect of extract of ginkgo biloba leaves on plasminogen activator inhibitor 1(pai-1)and thromboxane b2(txb-2)in type 2 diabetes mellitus(dm).

目的：观察银杏叶提取物对2型糖尿病病人纤溶酶原激活物抑制物1（pai1）及凝血烷b2（txb2 ）的影响。

objective to study the effects of transient cerebral ischemic reperfusion(ir) and flunarizine on the expression of plasminogen activator inhibitor-1(pai-1) protein in brain tissue of gerbils.

目的研究沙鼠脑缺血再灌注后脑内1型纤溶酶原激活物抑制剂（pai-1）蛋白表达变化，以及西比灵干预的影响。

plasma endothelin 1(et 1), tissue type plasminogen activator(t pa) and plasminogen activator inhibitor 1(pai 1) were studied before and after ecp.

观察ecp前后内皮源性血管活性物质内皮素-1（et-1）、组织型纤溶酶原激活物（t-pa）及其抑制剂（pai-1）的变化。

objective to study the expression of plasminogen activator inhibitor-1(pai-1) of the blood serum and plaques in atherosclerotic rabbits in order to explore the effect of pai-1 on atherosclerosis (as).

目的通过对动脉粥样硬化（as）兔血清和粥样硬化斑块中纤溶酶原激活物抑制物-1（pai-1）表达的研究，探讨pai-1在as中的作用。

objective: to identify the significance of urokinase-type plasminogen activator expression in patients with epithelial ovarian carcinoma.

目的：探讨尿激酶型纤溶酶原激活因子的蛋白表达与上皮性卵巢癌生物学行为的关系。

maybe liver softening-granules treated hepatic fibrosis by regulating the plasminogen activator system and hasten the fibrin dissolve.

柔肝沖剂可能通过影响纤溶酶原激活系统，起到抗肝纤维化作用。

objectiveto study the role and significance of plasminogen activator inhibitor-1(pai-1) in renal fibrosis(rf) after damage and elucidate the molecular pathogenetic mechanisms of rf.

为探讨纤溶酶原激活物抑制因子1（pai1）在肾损伤后纤维化中的作用和意义，揭示其发病的分子病理机制。

objective to investigate effects of two proinflammatory cytokines on the production of plasminogen activator inhibitor 1(pai 1) by human pleural mesothelial cells(hpmc).

目的研究前炎癥细胞因子对人胸膜间皮细胞（hpmc）释放纤溶酶原激活物抑制剂（pai1）的诱导效应。

objective to study the effects of atorvastatin cholesterol-lowering therapy on vascular endothelial function and plasminogen activator inhibitor-1 in acute coronary syndromes.

目的：探讨急性冠脉综合征患者应用阿托伐他汀调脂治疗后对血管内皮舒张功能、血浆纤溶酶原激活物抑制物1及血管内皮素1的影响。

objective to study the relationship of plasminogen activator inhibitor type 1(pai 1) to platelet activity in elderly patients with unstable angina pectoris(uap).

目的探讨老年不稳定型心绞痛（uap）与纤溶酶原激活物抑制剂1型（pai1）及血小板活化功能的临床意义。

objective: to investigate the protein expression of plasminogen activator inhibitor(pai 1) in renal tissue of hypercholesterolemia rats and the effect of irbesartan.

目的：①了解纤溶酶原激活物抑制剂1（pai1）在高胆固醇大鼠血及肾皮质的表达及其与肾脏损害的关系；

objective:to observe the urinary plasminogen activator (pa) excretion in 5/6 nephrectomized rats.

目的：了解5／6肾切除大鼠尿纤溶酶原激活物（pa）排泄量的动态变化。

plasminogen activator inhibitor-1(pai-1)is the main regulator of the fibrinolytic system.

血浆纤溶酶原激活物抑制剂（pai）-1是纤溶系统的主要调控因子。

plasminogen activator inhibitor-1(pai-1) is a single-chain glycoprotein secreted by many kinds of cells, which participates in many physiological process.

血浆纤溶酶原激活剂抑制物1（pai-1）是由多种细胞分泌的糖化蛋白，在体内参与多种生理过程。

objective:to examine whether vldl or ldl can stimulate the secretion of plasminogen activator inhibitor type 1 (pai-1) in hepatic cells.

目的：观察极低密度脂蛋白（vl dl）与低密度脂蛋白（l dl）是否能刺激肝细胞纤溶酶原激活物抑制物-1（pai-1）的分泌。

objective: to evaluate the efficacy and safety of recombinant tissue plasminogen activator in hyper acute cerebral infarction.

目的：评价重组组织型纤溶酶原激活剂治疗急性脑梗死的疗效及安全性。

the thrombolytic effect was compared between urokinase (uk) and human tissue plasminogen activator (t-pa) in rabbits with experimental iliofemoral artery thrombus.

本文用尿激酶（uk）和人体组织型纤溶酶原激活剂（t-pa）进行了兔髂股动脉血栓实验性溶解的对照研究。

plasminogen activator inhibitor-1 (pai-1) is one of the important components of the plasma fibrinolytic system and plays an key role in maintaining its stability.

纤溶酶原激活物抑制物1（pai-1）是血浆纤维蛋白溶解系统的重要组成物之一，对维持血浆纤溶系统的稳定起重要作用。

objective to monitor the dynamic changes of tissue type plasminogen activator(t-pa) and plasminogen activator inhibitor-i(pai-i) activity after and before ptca in patients with acs.

目的观察急性冠脉综合征（acs）患者冠脉成形术（ptca）前后血浆组织型纤溶酶原激活物（t-pa）及纤溶酶原激活抑制剂（pai-i）的动态变化。

objective to investigate the plasma tissue-type plasminogen activator(t-pa) and plasminogen activator inhibitor(pai) in coronary heart disease patients with angina pectoris and its probable mechanism.

目的探讨冠心病心绞痛病人血浆组织型纤溶酶原激活物（tpa）及其抑制物（pai）活性的变化及其可能机制。